HLA-C and neoplasm: A common theme for 4 of the Phase III trials (MAGRIT, START, START2, and TIME) is that only one highly immunogenic TAA was selected for each formulation, placing immense pressure on it to remain highly expressed by tumor cells and presentable on MHC molecules [121,122,141,147].